drugset / Trial / NCT06680830
A Phase 2 Study and Open-Label Extension of NEU-411 in Companion Diagnostic-Positive Participants With Early Parkinson's Disease
Phase 2
Recruiting
150 enrolled
Neuron23 Inc.
Qiagen Manchester Limited · collabRoche Diagnostic Ltd. · collab
RandomizedParallel-groupQuadruple-blindTreatment
Summary
The goal of this Phase 2 clinical trial is to investigate the efficacy and safety of NEU-411 in men and women aged 40-80 years with early Parkinson's Disease (PD) who have predicted elevations in the activity of the "leucine-rich repeat kinase 2" ("LRRK2" for short) pathway based on their genetic profile. A DNA test will be used to identify the "LRRK2-driven" population with predicted elevation in the LRRK2 pathway.
Timeline
- Start
- 2025-01-17
- Primary completion
- 2027-12
- Completion
- 2028-06
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | NEU-411 | Small molecule | 30 mg | Oral |